Pimavanserin – Nuplazid
Posted On March 29, 2020
- Reduce delusions in Parkinson disease patient
- 34 mg qd
- Approved in 2016
- not approved for the treatment of patients with dementia-related psychosis
- Strong cyp3a4 inhibitors
- Cost
- 34 mg 30 cap – $3400